Selected research
Industry Research
Biosimilar Industry Research Report 2026
Market perspective
The global Biosimilar market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biosimilar market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biosimilar market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biosimilar market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biosimilar include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biosimilar market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biosimilar.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biosimilar Market by Company
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Biosimilar Segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Biosimilar Segment by Application
Cancer
Immunological Diseases
Diabetes
Others
Biosimilar Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biosimilar companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biosimilar Monoclonal Antibodies
- Biosimilar Insulin
- Others
Applications
- Cancer
- Immunological Diseases
- Diabetes
- Others
Companies covered
- Qilu Pharmaceutical
- Bio-Thera
- Zhejiang Hisun
- Shanghai Henlius
- Innovent Biologics
- Jiangsu Hengrui
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
- 3SBIO
- Luye Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biosimilar by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Biosimilar Monoclonal Antibodies
- 2.2.3 Biosimilar Insulin
- 2.2.4 Others
- 2.3 Biosimilar by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Immunological Diseases
- 2.3.4 Diabetes
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Biosimilar Breakdown Data by Type
- 3.1 Global Biosimilar Historic Market Size by Type (2021-2026)
- 3.2 Global Biosimilar Forecasted Market Size by Type (2027-2032)
4 Biosimilar Breakdown Data by Application
- 4.1 Global Biosimilar Historic Market Size by Application (2021-2026)
- 4.2 Global Biosimilar Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biosimilar Market Perspective (2021-2032)
- 5.2 Global Biosimilar Growth Trends by Region
- 5.2.1 Global Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biosimilar Historic Market Size by Region (2021-2026)
- 5.2.3 Biosimilar Forecasted Market Size by Region (2027-2032)
- 5.3 Biosimilar Market Dynamics
- 5.3.1 Biosimilar Industry Trends
- 5.3.2 Biosimilar Market Drivers
- 5.3.3 Biosimilar Market Challenges
- 5.3.4 Biosimilar Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biosimilar Players by Revenue
- 6.1.1 Global Top Biosimilar Players by Revenue (2021-2026)
- 6.1.2 Global Biosimilar Revenue Market Share by Players (2021-2026)
- 6.2 Global Biosimilar Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biosimilar Head Office and Area Served
- 6.4 Global Biosimilar Players, Product Type & Application
- 6.5 Global Biosimilar Manufacturers Established Date
- 6.6 Global Biosimilar Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biosimilar Market Size (2021-2032)
- 7.2 North America Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biosimilar Market Size by Country (2021-2026)
- 7.4 North America Biosimilar Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biosimilar Market Size (2021-2032)
- 8.2 Europe Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biosimilar Market Size by Country (2021-2026)
- 8.4 Europe Biosimilar Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biosimilar Market Size (2021-2032)
- 9.2 Asia-Pacific Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biosimilar Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biosimilar Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biosimilar Market Size (2021-2032)
- 10.2 South America Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biosimilar Market Size by Country (2021-2026)
- 10.4 South America Biosimilar Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biosimilar Market Size (2021-2032)
- 11.2 Middle East & Africa Biosimilar Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biosimilar Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biosimilar Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Qilu Pharmaceutical
- 12.1.1 Qilu Pharmaceutical Company Information
- 12.1.2 Qilu Pharmaceutical Business Overview
- 12.1.3 Qilu Pharmaceutical Revenue in Biosimilar Business (2021-2026)
- 12.1.4 Qilu Pharmaceutical Biosimilar Product Portfolio
- 12.1.5 Qilu Pharmaceutical Recent Developments
- 12.2 Bio-Thera
- 12.2.1 Bio-Thera Company Information
- 12.2.2 Bio-Thera Business Overview
- 12.2.3 Bio-Thera Revenue in Biosimilar Business (2021-2026)
- 12.2.4 Bio-Thera Biosimilar Product Portfolio
- 12.2.5 Bio-Thera Recent Developments
- 12.3 Zhejiang Hisun
- 12.3.1 Zhejiang Hisun Company Information
- 12.3.2 Zhejiang Hisun Business Overview
- 12.3.3 Zhejiang Hisun Revenue in Biosimilar Business (2021-2026)
- 12.3.4 Zhejiang Hisun Biosimilar Product Portfolio
- 12.3.5 Zhejiang Hisun Recent Developments
- 12.4 Shanghai Henlius
- 12.4.1 Shanghai Henlius Company Information
- 12.4.2 Shanghai Henlius Business Overview
- 12.4.3 Shanghai Henlius Revenue in Biosimilar Business (2021-2026)
- 12.4.4 Shanghai Henlius Biosimilar Product Portfolio
- 12.4.5 Shanghai Henlius Recent Developments
- 12.5 Innovent Biologics
- 12.5.1 Innovent Biologics Company Information
- 12.5.2 Innovent Biologics Business Overview
- 12.5.3 Innovent Biologics Revenue in Biosimilar Business (2021-2026)
- 12.5.4 Innovent Biologics Biosimilar Product Portfolio
- 12.5.5 Innovent Biologics Recent Developments
- 12.6 Jiangsu Hengrui
- 12.6.1 Jiangsu Hengrui Company Information
- 12.6.2 Jiangsu Hengrui Business Overview
- 12.6.3 Jiangsu Hengrui Revenue in Biosimilar Business (2021-2026)
- 12.6.4 Jiangsu Hengrui Biosimilar Product Portfolio
- 12.6.5 Jiangsu Hengrui Recent Developments
- 12.7 Gan&Lee
- 12.7.1 Gan&Lee Company Information
- 12.7.2 Gan&Lee Business Overview
- 12.7.3 Gan&Lee Revenue in Biosimilar Business (2021-2026)
- 12.7.4 Gan&Lee Biosimilar Product Portfolio
- 12.7.5 Gan&Lee Recent Developments
- 12.8 Tonghua Dongbao
- 12.8.1 Tonghua Dongbao Company Information
- 12.8.2 Tonghua Dongbao Business Overview
- 12.8.3 Tonghua Dongbao Revenue in Biosimilar Business (2021-2026)
- 12.8.4 Tonghua Dongbao Biosimilar Product Portfolio
- 12.8.5 Tonghua Dongbao Recent Developments
- 12.9 United Laboratory
- 12.9.1 United Laboratory Company Information
- 12.9.2 United Laboratory Business Overview
- 12.9.3 United Laboratory Revenue in Biosimilar Business (2021-2026)
- 12.9.4 United Laboratory Biosimilar Product Portfolio
- 12.9.5 United Laboratory Recent Developments
- 12.10 3SBIO
- 12.10.1 3SBIO Company Information
- 12.10.2 3SBIO Business Overview
- 12.10.3 3SBIO Revenue in Biosimilar Business (2021-2026)
- 12.10.4 3SBIO Biosimilar Product Portfolio
- 12.10.5 3SBIO Recent Developments
- 12.11 Luye Pharma
- 12.11.1 Luye Pharma Company Information
- 12.11.2 Luye Pharma Business Overview
- 12.11.3 Luye Pharma Revenue in Biosimilar Business (2021-2026)
- 12.11.4 Luye Pharma Biosimilar Product Portfolio
- 12.11.5 Luye Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst